Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports
Author
Jefferson, TomJones, Mark A., B.Sc., Ph.D.
Doshi, Peter
Del Mar, Chris
Hama, Rokuro, M.D.
Thompson, Matthew J.
Onakpoya, Igho
Heneghan, Carl
Date
2014-09Publisher
BMJ Publishing GroupType
Article
Metadata
Show full item recordCitation
Jefferson, T., Jones, M.A., Doshi, P., et al. (2014). Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open, 4(9). DOI: 10.1136/bmjopen-2014-005253Identifier to cite or link to this item
http://hdl.handle.net/10713/6585ae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2014-005253
Scopus Count
Collections
Related articles
- Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
- Authors: Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ
- Issue date: 2014 Apr 9
- Research transparency: a moral obligation.
- Issue date: 2014 Jun
- Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review.
- Authors: Jørgensen L, Gøtzsche PC, Jefferson T
- Issue date: 2018 Jan 18
- Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews.
- Authors: Vale CL, Tierney JF, Burdett S
- Issue date: 2013 Apr 22
- Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
- Authors: Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T
- Issue date: 2016 May